It's a tiny business for Stryker, but one that has had problems over the years, including a Food and Drug Administration panel's rejection in March of Stryker's bid to use 'Op-1' bone-growth products more broadly. They are only approved in the U.S. today...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to UPDATE: Stryker Biotech Indicted Over Product Promotion
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account
account